Shiyu Capital is the famous VC, which was founded in 2014. The main department of described VC is located in the Beijing. The venture was found in Asia in China.
The usual cause for the fund is to invest in rounds with 3 partakers. Despite the Shiyu Capital, startups are often financed by Stone Capital, H&Q Asia Pacific. The meaningful sponsors for the fund in investment in the same round are Legend Capital, Zhuhai Huajin Asset, State Development & Investment Corporation (SDIC).
We can highlight the next thriving fund investment areas, such as Medical, Health Care. For fund there is a match between the location of its establishment and the land of its numerous investments - China. Among the most popular portfolio startups of the fund, we may highlight Biotheus. Besides, a startup requires to be at the age of 1 and less years to receive the investment from the fund.
The current fund was established by Calvin Cao, Hongbing Yang. Besides them, we counted 2 critical employees of this fund in our database.
The fund is constantly included in 2-6 deals per year. Deals in the range of 50 - 100 millions dollars are the general things for fund. Considering the real fund results, this VC is 37 percentage points more often commits exit comparing to other organizations. The typical startup value when the investment from Shiyu Capital is 500 millions - 1 billion dollars. The top activity for fund was in 2019.
Related Funds
Funds with similar focus
Fund Name | Location |
Brasil Venture Debt | Brazil, São Paulo, Sao Paulo |
Clark Ventures | Atlanta, Georgia, United States |
Dentsu Ventures | Chiyoda, Japan |
DIA Investments | - |
DM Wellness | - |
Eyrir Invest | Gullbringusysla, Iceland, Reykjavík |
Gainsight | California, San Francisco, United States |
Heads or Tails Investments | - |
i-nest capital | Japan, Tokyo |
Lacomp Plc | - |
Night Media | Dallas, Texas, United States |
P. Schoenfeld Asset Management | New York, New York, United States |
PRD Angels | - |
Primus Capital Partners | Cleveland, Ohio, United States |
Shanxi Wenhua Zichan | China, Shaanxi, Xian Shi |
Shengtai Xinli | Beijing, Beijing, China |
Technorov Holdings | - |
USC Marshall Venture Fund | California, Los Angeles, United States |
V-Guard Industries | India, Kerala, Kochi |
Zech Group | - |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Hainan Zhongle | $773K | 28 Feb 2024 | Haikou, Hainan, China | ||
$20M | 31 Mar 2021 | Shanghai, China | |||
Biotheus | 03 Mar 2021 | Xiangzhou District, Guangdong Province, China | |||
$150M | 23 Feb 2021 | Shanghai, China | |||
CARsgen Therapeutics | $186M | 02 Nov 2020 | Shanghai, China | ||
$278M | 29 Apr 2020 | China, Shanghai | |||
Lepu Bio | $139M | 02 Jul 2019 | Shanghai, China | ||
Biotheus | $15M | 26 Jun 2019 | Xiangzhou District, Guangdong Province | ||
Allist Pharmaceuticals | $185M | 24 May 2019 | China, Shanghai |
– OnQuality Pharmaceuticals LLC (“OnQuality”), a targeted cancer supportive care company developing medications to address specific side effects and improve the quality of life for patients receiving anti-cancer medications, today announced the closing of its Series A+ financing round securing an additional $20 million in funding. This brings the total amount of capital raised in Series A and A+ to $35 million.
– This financing round included participation from Shiyu Capital, Matrix Partners China, BioTrack Capital, CASH Capital, Sinovation Ventures, FreeS Fund, and additional biotech veterans.
– Proceeds from the financing will support the ongoing Phase II clinical trial of the company’s leading compound OQL011, as well as multiple additional targeted cancer supportive care programs anticipated to enter different phases of clinical development over the next 18 months.
OnQuality also announced the appointment of pharmaceutical executive Michael McCullar, Ph.
– WuXi Diagnostics secured a US$150m Series B financing round to accelerate market penetration in the global diagnostics sector.
– The round was joined by new investors including Thermo Fisher, Shiyu Capital, ABC International, Sunland Capital, and CCBI Tech Venture.
– WuXi Diagnostics will deploy funds to strengthen its open-access innovation enabling platform, advance its integrated diagnostics R&D pipeline, and accelerate market penetration in the global diagnostics sector.
– WuXi Diagnostics is the first platform company in China focusing on integrated diagnostics. Since its establishment in 2018, WuXi Diagnostics has continuously promoted the clinical practice of integrated diagnostics by virtue of its open-access innovation enabling platform, centered on multi-omics clinical data from multidisciplinary technologies.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Hainan Zhongle | $773K | 28 Feb 2024 | Haikou, Hainan, China | ||
$20M | 31 Mar 2021 | Shanghai, China | |||
Biotheus | 03 Mar 2021 | Xiangzhou District, Guangdong Province, China | |||
$150M | 23 Feb 2021 | Shanghai, China | |||
CARsgen Therapeutics | $186M | 02 Nov 2020 | Shanghai, China | ||
$278M | 29 Apr 2020 | China, Shanghai | |||
Lepu Bio | $139M | 02 Jul 2019 | Shanghai, China | ||
Biotheus | $15M | 26 Jun 2019 | Xiangzhou District, Guangdong Province | ||
Allist Pharmaceuticals | $185M | 24 May 2019 | China, Shanghai |